Skip to content
Search

Latest Stories

Pharmacy contractors can now use “flexible approach” in collecting patient feedback

All pharmacy contractors will now be able to use a more flexible approach while conducting an annual assessment of patient satisfaction, with no mandatory usage of the Community Pharmacy Patient Questionnaire (CPPQ) from 2022-23.

This follows an approval from the NHS England and NHS Improvement (NHSE&I) and the Department of Health and Social Care (DHSC) for the changes proposed by the Pharmaceutical Services Negotiating Committee (PSNC).


The detail has been set out in updated Approved Particulars for the annual patient experience survey.

With this, “contractors can now adopt a variety of methods for collecting that feedback, rather than having to use the CPPQ,” the negotiator said.

Alastair Buxton, PSNC director of NHS Services, said: “PSNC sought these changes to the requirements to address requests from contractors to have greater flexibility in the way they undertake surveys of patients’ experience of pharmacy services.

“They told us they wanted this flexibility so they could seek feedback which would provide better insights into what they could do to improve the experience of patients using their NHS services.”

Every year, before the start of the next financial year and by December 31, NHSE&I and PSNC will agree upon three topics which all contractors must include in their collection of feedback from patients in the following financial year’s satisfaction survey.

Currently, these topics are under discussion and the agreed list for 2022/23 will be published shortly, PSNC stated.

For 2021-22 assessment, contractors who have already undertaken the CPPQ survey, will be considered to have met the requirements for the year and need not take further action.

Meanwhile, other contractors still have the option to use the CPPQ in 2021/22 to meet the contractual requirements.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less